9th Annual Program Recognizes Boston Gene’s Multimodal AI Infrastructure to Reduce Risk and Accelerate Oncology Drug Development
Waltham, Massachusetts, July 7, 2026–(BUSINESS WIRE)–Boston Gene, a leading developer of AI models for oncology and immunobiology, today announced that it has been selected as the winner of the “Overall AI-Based Analytics Company of the Year” award in the 9th annual AI Breakthrough Awards Program conducted by AI Breakthrough, a leading market intelligence organization that recognizes the top companies, technologies, and products in today’s global artificial intelligence (AI) market.
The AI Breakthrough Awards have been researching, analyzing, and recognizing the most significant advances in artificial intelligence for nearly a decade, but this year’s field is the strongest yet. Thousands of nominations came in from more than 20 countries across categories such as agenttic AI, generative AI, computer vision, AIOps, robotics, natural language processing, and industry-specific AI applications, highlighting the explosive growth of AI globally and its importance as a defining technology of our time.
BostonGene’s integrated platform combines advanced AI models and CLIA/CAP-certified molecular profiling to transform complex tumor immunobiology into decision-ready insights. By incorporating detailed profiling of the transcriptome and immune system directly into clinical workflows, the platform serves as a critical decision-making infrastructure rather than a discovery tool. This integrated predictive framework allows biopharmaceutical companies to model treatment response, resistance, and safety in real time. Ultimately, this will move drug development from retrospective analysis to simulation-based strategies, while accelerating biomarker refinement, patient selection, and portfolio prioritization throughout the drug development lifecycle.
“We are focused on addressing the most enduring and high-stakes challenges in oncology, while anticipating and capitalizing on key trends,” said Andrew Feinberg, president and CEO of Boston Gene. “The effectiveness of our approach is reflected in outcomes such as improved portfolio focus, reduced development risk, the incorporation of immune-driven predictions into pre-therapy strategies to reduce risk, and clearer patient stratification.” “We thank AI Breakthrough for recognizing that we are redefining the way clinical and drug development decisions are made by moving from exploratory analytics to actionable decision-oriented intelligence.”
“BostonGene offers a robust and scalable approach to decision intelligence in oncology. Clinical programs experience high attrition rates and few assets reach market. Inaccurate patient stratification results in suboptimal outcomes and unnecessary toxicity, while development decisions made without sufficient biological filtering at the portfolio level inhibit promising therapies,” said Steve Johansson, Managing Director, AI Breakthrough. “Boston Gene is accelerating the delivery of life-saving treatments across the drug development lifecycle by enabling more informed development strategies, improved patient selection, and reduced uncertainty with AI.”
